MAP2K7 and colorectal carcinoma: We investigated the response of PDOs to three chemotherapeutic agents clinically used for the treatment of CRC harboring the BRAF V600E mutation9,26: binimetinib, encorafenib and cetuximab, which inhibit MEK, BRAF and EGFR, respectively.